VistaStem Therapeutics is the wholly owned subsidiary of VistaGen Therapeutics, Inc. (NASDAQ: VTGN) focused on applying our human pluripotent stem cell (hPSC) technology platform and CardioSafe 3D™, our customized in-vitro cardiac cell bioassay system, to predict potential heart toxicity of new chemical entities (NCEs) long before they are tested in preclinical animal studies and human clinical studies. Together with a select group of pharmaceutical and biotechnology companies focused on predictive cardiac toxicology, we are utilizing CardioSafe 3D in the FDA’s Comprehensive in-vitro Proarrhythmia Assay (CiPA) initiative, designed to change the landscape of preclinical drug development by providing a more complete and accurate assessment of potential drug effects on cardiac risk.

We are also leveraging our stem cell technology to discover, rescue, develop and commercialize small molecule NCEs for central nervous system (CNS) and other diseases including NCEs with regenerative potential, as well as innovative regenerative medicines and cellular therapies across a range of cell types, including blood, bone, cartilage, heart and liver cells. In December 2016, we entered into an exclusive sublicense agreement with BlueRock Therapeutics L.P, a next generation regenerative medicine company established by Bayer AG and Versant Ventures, for our rights to proprietary technologies relating to the production of cardiac stem cells for the treatment of heart disease.